130 related articles for article (PubMed ID: 21459170)
1. Proteomic studies on protein modification by cyclopentenone prostaglandins: expanding our view on electrophile actions.
Garzón B; Oeste CL; Díez-Dacal B; Pérez-Sala D
J Proteomics; 2011 Oct; 74(11):2243-63. PubMed ID: 21459170
[TBL] [Abstract][Full Text] [Related]
2. Modification of cysteine residues by cyclopentenone prostaglandins: interplay with redox regulation of protein function.
Oeste CL; Pérez-Sala D
Mass Spectrom Rev; 2014; 33(2):110-25. PubMed ID: 23818260
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory prostanoids: focus on the interactions between electrophile signaling and resolution of inflammation.
Díez-Dacal B; Pérez-Sala D
ScientificWorldJournal; 2010 Apr; 10():655-75. PubMed ID: 20419278
[TBL] [Abstract][Full Text] [Related]
4. Electrophilic prostaglandins: identification of protein targets and opportunities for drug discovery.
Pérez-Sala D
Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S8. PubMed ID: 26461419
[TBL] [Abstract][Full Text] [Related]
5. Prostanoids with cyclopentenone structure as tools for the characterization of electrophilic lipid-protein interactomes.
Stamatakis K; Pérez-Sala D
Ann N Y Acad Sci; 2006 Dec; 1091():548-70. PubMed ID: 17341644
[TBL] [Abstract][Full Text] [Related]
6. Differential selectivity of protein modification by the cyclopentenone prostaglandins PGA1 and 15-deoxy-Delta12,14-PGJ2: role of glutathione.
Gayarre J; Stamatakis K; Renedo M; Pérez-Sala D
FEBS Lett; 2005 Oct; 579(25):5803-8. PubMed ID: 16223487
[TBL] [Abstract][Full Text] [Related]
7. Study of protein targets for covalent modification by the antitumoral and anti-inflammatory prostaglandin PGA1: focus on vimentin.
Gharbi S; Garzón B; Gayarre J; Timms J; Pérez-Sala D
J Mass Spectrom; 2007 Nov; 42(11):1474-84. PubMed ID: 17960581
[TBL] [Abstract][Full Text] [Related]
8. Protein disulfide isomerase as a novel target for cyclopentenone prostaglandins: implications for hypoxic ischemic injury.
Liu H; Chen J; Li W; Rose ME; Shinde SN; Balasubramani M; Uechi GT; Mutus B; Graham SH; Hickey RW
FEBS J; 2015 May; 282(10):2045-59. PubMed ID: 25754985
[TBL] [Abstract][Full Text] [Related]
9. A biotinylated analog of the anti-proliferative prostaglandin A1 allows assessment of PPAR-independent effects and identification of novel cellular targets for covalent modification.
Garzón B; Gayarre J; Gharbi S; Díez-Dacal B; Sánchez-Gómez FJ; Timms JF; Pérez-Sala D
Chem Biol Interact; 2010 Jan; 183(1):212-21. PubMed ID: 19800325
[TBL] [Abstract][Full Text] [Related]
10. Modification of proteins by cyclopentenone prostaglandins is differentially modulated by GSH in vitro.
Gayarre J; Avellano MI; Sánchez-Gómez FJ; Carrasco MJ; Cañada FJ; Pérez-Sala D
Ann N Y Acad Sci; 2007 Jan; 1096():78-85. PubMed ID: 17405918
[TBL] [Abstract][Full Text] [Related]
11. Lipoxidation adducts with peptides and proteins: deleterious modifications or signaling mechanisms?
Domingues RM; Domingues P; Melo T; Pérez-Sala D; Reis A; Spickett CM
J Proteomics; 2013 Oct; 92():110-31. PubMed ID: 23770299
[TBL] [Abstract][Full Text] [Related]
12. Nitric Oxide and Electrophilic Cyclopentenone Prostaglandins in Redox signaling, Regulation of Cytoskeleton Dynamics and Intercellular Communication.
Bago Á; Íñiguez MA; Serrador JM
Front Cell Dev Biol; 2021; 9():673973. PubMed ID: 34026763
[TBL] [Abstract][Full Text] [Related]
13. The C-terminus of H-Ras as a target for the covalent binding of reactive compounds modulating Ras-dependent pathways.
Oeste CL; Díez-Dacal B; Bray F; García de Lacoba M; de la Torre BG; Andreu D; Ruiz-Sánchez AJ; Pérez-Inestrosa E; García-Domínguez CA; Rojas JM; Pérez-Sala D
PLoS One; 2011 Jan; 6(1):e15866. PubMed ID: 21253588
[TBL] [Abstract][Full Text] [Related]
14. Direct evidence for the covalent modification of glutathione-S-transferase P1-1 by electrophilic prostaglandins: implications for enzyme inactivation and cell survival.
Sánchez-Gómez FJ; Gayarre J; Avellano MI; Pérez-Sala D
Arch Biochem Biophys; 2007 Jan; 457(2):150-9. PubMed ID: 17169324
[TBL] [Abstract][Full Text] [Related]
15. Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
Díez-Dacal B; Sánchez-Gómez FJ; Sánchez-Murcia PA; Milackova I; Zimmerman T; Ballekova J; García-Martín E; Agúndez JA; Gharbi S; Gago F; Stefek M; Pérez-Sala D
Mol Pharmacol; 2016 Jan; 89(1):42-52. PubMed ID: 26487510
[TBL] [Abstract][Full Text] [Related]
16. Cyclopentenone: a special moiety for anticancer drug design.
Conti M
Anticancer Drugs; 2006 Oct; 17(9):1017-22. PubMed ID: 17001173
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel protein targets for modification by 15-deoxy-Delta12,14-prostaglandin J2 in mesangial cells reveals multiple interactions with the cytoskeleton.
Stamatakis K; Sánchez-Gómez FJ; Pérez-Sala D
J Am Soc Nephrol; 2006 Jan; 17(1):89-98. PubMed ID: 16291835
[TBL] [Abstract][Full Text] [Related]
18. 15-Deoxy-Δ¹²,¹⁴-prostaglandin J₂ as an electrophilic mediator.
Shibata T
Biosci Biotechnol Biochem; 2015; 79(7):1044-9. PubMed ID: 26011133
[TBL] [Abstract][Full Text] [Related]
19. Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins.
Gutierrez LL; Maslinkiewicz A; Curi R; de Bittencourt PI
Biochem Pharmacol; 2008 Jun; 75(12):2245-62. PubMed ID: 18440492
[TBL] [Abstract][Full Text] [Related]
20. Linking protein oxidation to environmental pollutants: redox proteomic approaches.
Braconi D; Bernardini G; Santucci A
J Proteomics; 2011 Oct; 74(11):2324-37. PubMed ID: 21767673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
